Icosavax to Participate in the Evercore ISI HealthCONx Conference

Rhea-AI Summary

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company focused on developing vaccines for respiratory diseases, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. CEO Adam Simpson will engage in a fireside chat on December 1 at 3:55 pm ET. Attendees can access a live audio webcast from the company's Investor Relations webpage, with a replay available for 90 days post-event. Icosavax aims to create multivalent vaccines using its innovative virus-like particle (VLP) technology.

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the 5^th Annual Evercore ISI HealthCONx Conference taking place November 29 through December 1, 2022.

Adam Simpson, Chief Executive Officer of Icosavax, is scheduled to participate in an analyst led fireside chat on Thursday, December 1 at 3:55 pm ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replay will be available following the conclusion of the presentation for approximately 90 days.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as programs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit www.icosavax.com.

Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091

Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620

FAQ

What is Icosavax's focus for vaccine development?

Icosavax focuses on developing vaccines against life-threatening respiratory diseases using its virus-like particle (VLP) platform technology.

When will Icosavax participate in the Evercore ISI HealthCONx Conference?

Icosavax will participate in the Evercore ISI HealthCONx Conference from November 29 to December 1, 2022.

What time is Adam Simpson's fireside chat at the conference?

Adam Simpson's fireside chat is scheduled for December 1, 2022, at 3:55 pm ET.

Where can I watch the Icosavax conference webcast?

The Icosavax conference webcast can be accessed through the Investor Relations section of their website.

What technology does Icosavax use for vaccine development?

Icosavax uses innovative virus-like particle (VLP) technology designed for the multivalent display of viral antigens to induce broad protection.